BioSpace News Archive

Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper, MBBS, as Senior Vice President, Chief Medical Officer, effective March 1, 2021. In this role, Dr. Cooper will oversee the Company’s medical and clinical activities relating to the potential regulatory approval of belumosudil

Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the upcoming Cowen 41 st Annual Healthcare Conference and the Oppenheimer 31 st Annual Healthcare Conference on March 4 th and March 16 th , respectively.

CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the US Food and Drug Administration (FDA) cannot approve the New Drug Application (NDA) for DefenCath™ (taurolidine/heparin catheter lock solution) in its present form

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that it will participate in the following investor conferences in the month of March, with presentations led by the Company’s President and Chief Executive Officer, Rodney Varner.

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced the publication of the results of both pivotal studies for PyL™

Anokion SA , a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the publication of data highlighting the company’s original erythrocyte binding technology in Science Immunology

ATW Tech Inc. (the “Company” or “ATW Tech”) (TSX-V: ATW) is pleased to announce the appointment of Mr. Christian Trudeau as Chairman of the Board of Directors of the Company to replace Mr. Michel Guay, who was holding the position on an interim basis.

Feb 27th, 2021, the U.S. Food and Drug Administration granted IND approval for Q-1802 from QureBio.Ltd. Q-1802 is a bispecific antibody which can target PD-L1 and Claudin18.2 simultaneously.

INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the Company has received approval by COFEPRIS to import INVOcell into Mexico

Essity, a leading global hygiene and health company, announces its Cutimed® Sorbact®, has received a 2021 Innovative Technology contract from Vizient, Inc., the largest member-driven, healthcare performance improvement company in the United States.